Brii Biosciences' (HKG:2137) said a group of phase 2 trial enrollees of a chronic hepatitis B treatment plan showed immune responsiveness after taking the company's BRII-179 drug, according to a Thursday filing with the Hong Kong bourse.
The data from cohort 4 of the study are "encouraging," Chief Medical Officer David Margolis said during the presentation of data during a congress in Amsterdam, the Netherlands.
The trial assessed the efficacy of the drug, together with a combination of elebsiran and pegylated interferon alpha in patients with chronic hepatitis B, the filing said.
"We saw in target populations that patients who were immune-responsive through pre-treatment with BRII-179 demonstrated a significant advantage in achieving a higher HBsAg seroclearance rate," said Margolis.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。